Based on a completed FDA review of a large randomized safety clinical trial, the FDA has concluded there is an increased risk of serious heart-related events such as… read more.
Roche announced that the European Commission (EC) has approved Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients two months of age and older,… read more.
Interview and article by Christine Clark. Dr Megan Hanlon and Professor Ursula Fearon describe the implications of their research findings for future practice and research in rheumatoid arthritis…. read more.
Interview and article by Christine Clark. Recent research into the molecular basis for rheumatoid arthritis may be pointing the way to targeted therapy to prevent inflammation and joint… read more.
Interview and article by Christine Clark A recent Canadian study examining comorbidities before and after the diagnosis of rheumatoid arthritis (RA) used distance matrices to match RA cases… read more.
Interview and article by Chrstine Clark The findings of a recent Canadian study examining comorbidities before and after the diagnosis of rheumatoid arthritis (RA) could have important implications… read more.
Interview and article by Christine Clark A recent Canadian study examining comorbidities before and after the diagnosis of rheumatoid arthritis (RA) produced a number of interesting findings, Dr… read more.
Interview and article by Christine Clark. Rheumatoid arthritis (RA) affects about one percent of the population in the UK and comorbidities are reported to be common. A recent… read more.
Article written by Bruce Sylvester Researchers report that methotrexate is an effective treatment for people with knee osteoarthritis (OA) who have pain and inflammation.
Article written by Bruce Sylvester Hydroxychloroquine treatment for lupus has no significant impact on heart rhythm, researchers reported on Nov 2, 2020 at the American College of Rheumatology/ACR… read more.
A study by O’Leary and colleagues, which appears in Arthritis Care & Research, looks at sedentary behaviour in people with RA and factors that may be associated with it.
In a study by Rebecca Rothwell and colleagues, which appears in Arthritis & Rheumatology, possible considerations of non-inferiority (NI) trials assessing treatment effects in RA are discussed.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
